{'fraction_non_alphanumeric': 0.021528525296017224, 'fraction_numerical': 0.002152852529601722, 'mean_word_length': 5.940298507462686, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The possibility of dexrazoxane to prevent ovarian damage caused by toxicity

ABSTRACT Dexrazoxane (Dexra), a catalytic topoisomerase II inhibitor and strong chelator, has been safely used in the clinic to decrease cardiotoxicity and extravasation caused by the anthracycline class of chemotherapy agents. Dexra also effectively shields the ovary from doxorubicin (DXR) chemotherapy at a dose 10-fold lower than that clinically approved for cardioprotection, ameliorating concerns that this chemoprotectant may diminish anti-tumor efficacy or increase risk for secondary malignancies. Dexra prevents acute DNA damage caused by DXR in the ovary, prolongs the reproductive lifespan of the adult female mouse post-chemotherapy, and improves offspring health. Cross-application of clinically-approved Dexra pretreatment demonstrates timely drug-based ovoprotection can be clinically implemented to improve quality of life post-cancer.